Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Genomic Predictors of Papillary Microcarcinoma Disease Progression

Recruiting

Conditions: Papillary Microcarcinoma

First Posted Date: 2015-02-16

Last Posted Date: 2024-12-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 500

Registration Number: NCT02363595

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Animal Assisted Activity Program on Patients and Staff on an Inpatient Surgical Oncology Unit

Completed

Conditions: Postoperative Care

Interventions: Other: standard post surgery care
Behavioral: Caring Canine program
Behavioral: baseline and post assessment

First Posted Date: 2015-02-16

Last Posted Date: 2017-01-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 146

Registration Number: NCT02363608

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Not Applicable

Terminated

Conditions: Non-Hodgkin's Lymphoma
Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Cyclophosphamide

First Posted Date: 2015-02-10

Last Posted Date: 2019-07-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT02360111

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Conditions: Neuroendocrine Tumors

First Posted Date: 2015-02-06

Last Posted Date: 2016-11-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02358018

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy

Not Applicable

Completed

Conditions: Insomnia
Cancer

Interventions: Other: Acupuncture
Other: Cognitive Behavior Therapy

First Posted Date: 2015-02-05

Last Posted Date: 2022-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 160

Registration Number: NCT02356575

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Phase 2

Completed

Conditions: Advanced Stage Non-small Cell Lung Cancer

Interventions: Drug: nivolumab
Drug: pilimumab

First Posted Date: 2015-01-30

Last Posted Date: 2024-05-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT02350764

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Hematopoietic Stem Cell Transplant
Poor Marrow Graft Function

Interventions: Device: CliniMACS Cell Selection System

First Posted Date: 2015-01-30

Last Posted Date: 2018-10-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT02350777

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Phase 1

Active, not recruiting

Conditions: Neuroendocrine Tumors

Interventions: Radiation: 18F-MFBG (meta-fluoro benzylguanidine)
Device: Positron emission tomography (PET) imaging
Other: Blood draws

First Posted Date: 2015-01-28

Last Posted Date: 2024-04-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT02348749

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase 1

Completed

Conditions: T-cell Lymphomas
Relapsed or Refractory

Interventions: Drug: Carfilzomib
Drug: Romidepsin
Drug: Lenalidomide

First Posted Date: 2015-01-19

Last Posted Date: 2024-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT02341014

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 3 locations

Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies

Phase 3

Completed

Conditions: Pancreatic Cancer
Unresectable Biliary-pancreatic Malignancies

Interventions: Device: ERCP with SEMS alone (standard of care)
Device: ERCP with SEMS plus radiofrequency ablation

First Posted Date: 2015-01-19

Last Posted Date: 2020-10-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT02340728

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy